Fabtech Technologies IPO Opens On September 29: Here’s What SWOT Analysis, Latest GMP Says

The initial public offering (IPO) of biopharma engineering company Fabtech Technologies is set to open for public bidding on September 29, and close on October 1.

The grey market premium (GMP) of the Fabtech Technologies shares suggests strong listing gains, according to websites that track such trades.

Here are the key details investors should know before applying to the Fabtech Technologies IPO.

Fabtech Technologies IPO Details

Fabtech Technologies IPO Issue Size

Fabtech Technologies plans to raise Rs 230.35 through the IPO, which includes the issuance of 12.06 million entirely fresh equity shares.

Fabtech Technologies IPO Price Band, Lot Size

Fabtech Technologies IPO shares are being offered with a price band of Rs 181 to Rs 191 per share with a lot size of 75. Retail investors are required to invest at least Rs 14,325 to apply for Fabtech Technologies IPO.

Fabtech Technologies IPO Allotment Date

The basis of allotment for Fabtech Technologies IPO is expected to be finalised by October 3, and the initiation of refunds for non-allottees will be done on October 6.

Fabtech Technologies IPO Listing Date

Shares of Fabtech Technologies are set to list on both the bourses – National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) – on October 7.

Fabtech Technologies IPO BRLM, Registrar

Unistone Capital is the book-running lead manager for Fabtech Technologies IPO, and Bigshare Services is the registrar.

Fabtech Technologies IPO GMP Today

According to multiple websites that track grey market activities, Fabetch Technologies IPO is trading with a GMP of Rs 35 over the issue price. Given the current GMP and the upper band of Rs 191 of the issue price, Fabtech Technologies IPO shares are likely to debut at Rs 226 per share, a potential listing gain of 18.32 per cent.

Fabtech Technologies IPO Financial Performance

Fabtech Technologies' revenue from operations for FY25 came in at Rs 326.66 crore, up from Rs 226.14 crore in FY24, and Rs 193.79 crore in FY23. This translates into a compounded annual growth rate (CAGR) of 29.83 per cent.

The company's profit after tax (PAT) stood at Rs 46.45 crore in FY25, up from Rs 27.22 crore in FY23, and Rs 21.73 crore in FY23, registering a CAGR of 46.20 per cent.

The company's net worth stood at Rs 173.11 crore, and its net debt stood at Rs 54.62 crore, as of March 31, 2025.

Fabtech Technologies SWOT Analysis

Strengths: Fabtech Technologies is a biopharma engineering company, which builds turnkey engineering projects for pharma and biotech clients. The company offers end-to-end services, from design and procurement to installation and commissioning, and provides “comprehensive start to finish execution of controlled environment infrastructure” for pharma, biotech, and healthcare clients across geographies.

The company says in its red herring prospectus (RHP) that its wide portfolio of offerings and global presence gives it "an edge in securing global mandates." According to the RHP, the company has an efficient lead funnelling process, which it says helps in higher mandate conversion.

Weaknesses: However, a large chunk of its revenue is concentrated in a few projects, making it dependent on timely execution. In FY25, the top five projects contributed more than half of its revenues.

Fabtech also has a relatively short operating history in its current form, having taken shape after a demerger in 2020. Further, the company in its RHP says, delays in converting leads into firm orders have in the past affected business momentum.

Opportunities: Pharma companies are spending more on expansion, and the government is supporting the sector with schemes like the Production-Linked Incentive (PLI) scheme (PLI) and creation of new pharma parks.

Domestic pharma-related capex is expected to grow about 1.5x to Rs 1,400–1,450 billion over FY26–30, the company says in its RHP. Fabtech is also looking to expand internationally by setting up joint ventures and participating in global industry exhibitions.

Threats: The company operates in a heavily regulated industry, where compliance with standards like Good Manufacturing Practice (GMP) and approvals from agencies such as the United States Food and Drug Administration (US FDA) are mandatory. Any changes in regulations and norms could affect its business.

Further, geopolitical instability or conflicts in regions where the company operates can disrupt supply chains and delay project execution.

The company also noted in its RHP that hiring and retaining talent in its line of business is also a challenge due to limited supply of skilled professionals.